4.6 Article Proceedings Paper

Gating of two pore domain potassium channels

期刊

JOURNAL OF PHYSIOLOGY-LONDON
卷 588, 期 17, 页码 3149-3156

出版社

WILEY-BLACKWELL
DOI: 10.1113/jphysiol.2010.192344

关键词

-

向作者/读者索取更多资源

Two-pore-domain potassium (K2P) channels are responsible for background leak currents which regulate the membrane potential and excitability of many cell types. Their activity is modulated by a variety of chemical and physical stimuli which act to increase or decrease the open probability of individual K2P channels. Crystallographic data and homology modelling suggest that all K+ channels possess a highly conserved structure for ion selectivity and gating mechanisms. Like other K+ channels, K2P channels are thought to have two primary conserved gating mechanisms: an inactivation (or C-type) gate at the selectivity filter close to the extracellular side of the channel and an activation gate at the intracellular entrance to the channel involving key, identified, hinge glycine residues. Zinc and hydrogen ions regulate Drosophila KCNK0 and mammalian TASK channels, respectively, by interacting with the inactivation gate of these channels. In contrast, the voltage dependence of TASK3 channels is mediated through its activation gate. For KCNK0 it has been shown that the gates display positive cooperativity. It is of much interest to determine whether other K2P regulatory compounds interact with either the activation gate or the inactivation gate to alter channel activity or, indeed, whether additional regulatory gating pathways exist.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Review Pharmacology & Pharmacy

Two-Pore Domain Potassium Channels as Drug Targets: Anesthesia and Beyond

Alistair Mathie, Emma L. Veale, Kevin P. Cunningham, Robyn G. Holden, Paul D. Wright

Summary: K2P channels play a crucial role in regulating cell activity and pharmacological modulation of these channels could be beneficial for various conditions. Recent studies on K2P channel structures and small-molecule compounds provide insights for the development of selective activators and inhibitors targeting these channels.

ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 61, 2021 (2021)

Article Pharmacology & Pharmacy

THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: Enzymes

Stephen P. H. Alexander, Doriano Fabbro, Eamonn Kelly, Alistair Mathie, John A. Peters, Emma L. Veale, Jane F. Armstrong, Elena Faccenda, Simon D. Harding, Adam J. Pawson, Christopher Southan, Jamie A. Davies, Detlev Boison, Kathryn Elisa Burns, Carmen Dessauer, Jurg Gertsch, Nuala Ann Helsby, Angelo A. Izzo, Doris Koesling, Rennolds Ostrom, Nigel J. Pyne, Susan Pyne, Michael Russwurm, Roland Seifert, Johannes-Peter Stasch, Mario van der Stelt, Albert van der Vliet, Val Watts, Szu Shen Wong

Summary: The Concise Guide to PHARMACOLOGY 2021/22 provides concise overviews of nearly 1900 human drug targets, with an emphasis on selective pharmacology, linking to an open access knowledgebase for more detailed information. Produced in collaboration with NC-IUPHAR, it offers official IUPHAR classification and nomenclature for human drug targets.

BRITISH JOURNAL OF PHARMACOLOGY (2021)

Article Pharmacology & Pharmacy

THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: Catalytic receptors

Stephen P. H. Alexander, Doriano Fabbro, Eamonn Kelly, Alistair Mathie, John A. Peters, Emma L. Veale, Jane F. Armstrong, Elena Faccenda, Simon D. Harding, Adam J. Pawson, Christopher Southan, Jamie A. Davies, Annie Beuve, Peter Brouckaert, Clare Bryant, John C. Burnett, Richard W. Farndale, Andreas Friebe, John Garthwaite, AdrianJ Hobbs, Gavin E. Jarvis, Michaela Kuhn, David MacEwan, Tom P. Monie, Andreas Papapetropoulos, Lincoln R. Potter, Harald H. H. W. Schmidt, Csaba Szabo, Scott A. Waldman

Summary: The Concise Guide to PHARMACOLOGY 2021/22 is the fifth edition in a biennial series, offering concise overviews of nearly 1900 human drug targets with an emphasis on selective pharmacology. It is designed for easy comparison of related targets and provides nomenclature guidance, summary information on pharmacological tools, and suggestions for further reading. The guide is produced in collaboration with the NC-IUPHAR to provide official classification and nomenclature for human drug targets.

BRITISH JOURNAL OF PHARMACOLOGY (2021)

Article Pharmacology & Pharmacy

THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: G protein-coupled receptors

Stephen P. H. Alexander, Arthur Christopoulos, Anthony P. Davenport, Eamonn Kelly, Alistair Mathie, John A. Peters, Emma L. Veale, Jane F. Armstrong, Elena Faccenda, Simon D. Harding, Adam J. Pawson, Christopher Southan, Jamie A. Davies, Maria Pia Abbracchio, Wayne Alexander, Khaled Al-hosaini, Magnus Baeck, Nicholas M. Barnes, Ross Bathgate, Jean-Martin Beaulieu, Kenneth E. Bernstein, Bernhard Bettler, Nigel J. M. Birdsall, Victoria Blaho, Francois Boulay, Corinne Bousquet, Hans Braeuner-Osborne, Geoffrey Burnstock, Girolamo Calo, Justo P. Castano, KevinJ Catt, Stefania Ceruti, Paul Chazot, Nan Chiang, Bice Chini, Jerold Chun, Antonia Cianciulli, Olivier Civelli, Lucie H. Clapp, Rejean Couture, Zsolt Csaba, Claes Dahlgren, Gordon Dent, Khuraijam Dhanachandra Singh, Steven D. Douglas, Pascal Dournaud, Satoru Eguchi, Emanuel Escher, Edward J. Filardo, Tung Fong, Marta Fumagalli, Raul R. Gainetdinov, Marc de Gasparo, Craig Gerard, Marvin Gershengorn, Fernand Gobeil, Theodore L. Goodfriend, Cyril Goudet, Karen J. Gregory, Andrew L. Gundlach, Joerg Hamann, Julien Hanson, Richard L. Hauger, Debbie L. Hay, Akos Heinemann, Morley D. Hollenberg, Nicholas D. Holliday, Mastgugu Horiuchi, Daniel Hoyer, Laszlo Hunyady, Ahsan Husain, Adriaan P. IJzerman, Tadashi Inagami, Kenneth A. Jacobson, Robert T. Jensen, Ralf Jockers, Deepa Jonnalagadda, Sadashiva Karnik, Klemens Kaupmann, Jacqueline Kemp, Charles Kennedy, Yasuyuki Kihara, Takio Kitazawa, Pawel Kozielewicz, Hans-Juergen Kreienkamp, Jyrki P. Kukkonen, Tobias Langenhan, Katie Leach, Davide Lecca, John D. Lee, Susan E. Leeman, Jerome Leprince, Xaria X. Li, Tom Lloyd Williams, Stephen J. Lolait, Amelie Lupp, Robyn Macrae, Janet Maguire, Jean Mazella, Craig A. McArdle, Shlomo Melmed, Martin C. Michel, Laurence J. Miller, Vincenzo Mitolo, Bernard Mouillac, Christa E. Mueller, Philip Murphy, Jean-Louis Nahon, Tony Ngo, Xavier Norel, Duuamene Nyimanu, Anne-Marie Ocarroll, Stefan Offermanns, Maria Antonietta Panaro, Marc Parmentier, Roger G. Pertwee, Jean-Philippe Pin, Eric R. Prossnitz, Mark Quinn, Rithwik Ramachandran, Manisha Ray, Rainer K. Reinscheid, Philippe Rondard, G. Enrico Rovati, Chiara Ruzza, Gareth J. Sanger, Torsten Schoeneberg, Gunnar Schulte, Stefan Schulz, Deborah L. Segaloff, Charles N. Serhan, Leigh A. Stoddart, Yukihiko Sugimoto, Roger Summers, Valerie P. Tan, David Thal, Walter (Wally) Thomas, PieterB M. W. M. Timmermans, Kalyan Tirupula, Giovanni Tulipano, Hamiyet Unal, Thomas Unger, Celine Valant, Patrick Vanderheyden, David Vaudry, Hubert Vaudry, Jean-Pierre Vilardaga, Christopher S. Walker, Ji Ming Wang, Donald T. Ward, Hans-Juergen Wester, Gary B. Willars, Trent M. Woodruff, Chengcan Yao, Richard D. Ye

Summary: The Concise Guide to PHARMACOLOGY 2021/22 presents concise overviews of nearly 1900 human drug targets with an emphasis on selective pharmacology, along with links to a more detailed knowledgebase. It serves as a permanent, citable record for researchers, providing useful information in the field of pharmacology.

BRITISH JOURNAL OF PHARMACOLOGY (2021)

Article Pharmacology & Pharmacy

THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: Nuclear hormone receptors

Stephen P. H. Alexander, John A. Cidlowski, Eamonn Kelly, Alistair Mathie, John A. Peters, Emma L. Veale, Jane F. Armstrong, Elena Faccenda, Simon D. Harding, Adam J. Pawson, Christopher Southan, Jamie A. Davies, Laurel Coons, Peter J. Fuller, Kenneth S. Korach, Morag J. Young

Summary: The Concise Guide to PHARMACOLOGY 2021/22 offers concise overviews of nearly 1900 human drug targets, predominantly in tabular format, emphasizing on selective pharmacology. The guide provides a simplified, citable record compared to the website information, and is designed for comparison of related targets from mid-2021.

BRITISH JOURNAL OF PHARMACOLOGY (2021)

Article Pharmacology & Pharmacy

THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: Transporters

Stephen P. H. Alexander, Eamonn Kelly, Alistair Mathie, John A. Peters, Emma L. Veale, Jane F. Armstrong, Elena Faccenda, Simon D. Harding, Adam J. Pawson, Christopher Southan, Jamie A. Davies, Laura Amarosi, Catriona M. H. Anderson, Philip Mark Beart, Stefan Broer, Paul A. Dawson, Bruno Hagenbuch, James R. Hammond, Ken-ichi Inui, Yoshikatsu Kanai, Stephan Kemp, Gavin Stewart, David T. Thwaites, Tiziano Verri

Summary: The Concise Guide to PHARMACOLOGY 2021/22 is a comprehensive publication providing concise overviews of nearly 1900 human drug targets with an emphasis on selective pharmacology. It covers six major pharmacological targets, offering information on the best available pharmacological tools and suggestions for further reading. The guide is a valuable resource for researchers and professionals in the field of pharmacology.

BRITISH JOURNAL OF PHARMACOLOGY (2021)

Article Pharmacology & Pharmacy

The Prostacyclin Analogue, Treprostinil, Used in the Treatment of Pulmonary Arterial Hypertension, is a Potent Antagonist of TREK-1 and TREK-2 Potassium Channels

Kevin P. Cunningham, Lucie H. Clapp, Alistair Mathie, Emma L. Veale

Summary: Pulmonary arterial hypertension (PAH) is a severe vascular remodeling disease with high morbidity and mortality rates. Treprostinil is an FDA and WHO approved treatment for PAH, but its limitation includes potential severe pain in some patients which may affect compliance.

FRONTIERS IN PHARMACOLOGY (2021)

Article Biochemistry & Molecular Biology

Aprepitant is a novel, selective activator of the K2P channel TRAAK

D. McCoull, E. L. Veale, Y. Walsh, L. Byrom, T. Avkiran, J. M. Large, E. Vaitone, F. Gaffey, J. Jerman, A. Mathie, P. D. Wright

Summary: TRAAK, a mechanosensitive potassium channel, is a potential target for novel analgesics. Aprepitant was identified through high throughput screening as a small molecule activator of TRAAK, demonstrating selectivity and no activation of other K2P channels.

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2022)

Article Genetics & Heredity

Gain and loss of TASK3 channel function and its regulation by novel variation cause KCNK9 imprinting syndrome

Margot A. Cousin, Emma L. Veale, Nikita R. Dsouza, Swarnendu Tripathi, Robyn G. Holden, Maria Arelin, Geoffrey Beek, Mir Reza Bekheirnia, Jasmin Beygo, Vikas Bhambhani, Martin Bialer, Stefania Bigoni, Cyrus Boelman, Jenny Carmichael, Thomas Courtin, Benjamin Cogne, Ivana Dabaj, Diane Doummar, Laura Fazilleau, Alessandra Ferlini, Ralitza H. Gavrilova, John M. Graham, Tobias B. Haack, Jane Juusola, Sarina G. Kant, Saima Kayani, Boris Keren, Petra Ketteler, Chiara Kloeckner, Tamara T. Koopmann, Teresa M. Kruisselbrink, Alma Kuechler, Laetitia Lambert, Xenia Latypova, Robert Roger Lebel, Magalie S. Leduc, Emanuela Leonardi, Andrea M. Lewis, Wendy Liew, Keren Machol, Samir Mardini, Kirsty McWalter, Cyril Mignot, Julie McLaughlin, Alessandra Murgia, Vinodh Narayanan, Caroline Nava, Sonja Neuser, Mathilde Nizon, Davide Ognibene, Joohyun Park, Konrad Platzer, Celine Poirsier, Maximilian Radtke, Keri Ramsey, Cassandra K. Runke, Maria J. Guillen Sacoto, Fernando Scaglia, Marwan Shinawi, Stephanie Spranger, Ee Shien Tan, John Taylor, Anne-Sophie Trentesaux, Filippo Vairo, Rebecca Willaert, Neda Zadeh, Raul Urrutia, Dusica Babovic-Vuksanovic, Michael T. Zimmermann, Alistair Mathie, Eric W. Klee

Summary: This study describes the mechanisms underlying KCNK9 imprinting syndrome (KIS) by identifying 15 novel KCNK9 alterations from 47 KIS-affected individuals. The study reveals the broader genetic and phenotypic variability for KIS and demonstrates the impact of KCNK9 variants on TASK3 channel function and regulation.

GENOME MEDICINE (2022)

Article Cell Biology

HIV and Schistosoma Co-Exposure Leads to Exacerbated Pulmonary Endothelial Remodeling and Dysfunction Associated with Altered Cytokine Landscape

Sandra Medrano-Garcia, Daniel Morales-Cano, Bianca Barreira, Alba Vera-Zambrano, Rahul Kumar, Djuro Kosanovic, Ralph Theo Schermuly, Brian B. Graham, Francisco Perez-Vizcaino, Alistair Mathie, Rajkumar Savai, Soni Pullamseti, Ghazwan Butrous, Edgar Fernandez-Malave, Angel Cogolludo

Summary: HIV and Schistosoma co-infection has a significant impact on pulmonary vascular disease, as shown in this study using an animal model. Co-infected mice exhibited increased pulmonary arterial pressure, impaired endothelial function, vessel obstructions, and perivascular fibrosis. Additionally, the immune response was compromised and cytokine expression was altered, leading to aggravated pulmonary vascular pathology.
Article Pharmacology & Pharmacy

A KCNB1 gain of function variant causes developmental delay and speech apraxia but not seizures

Emma L. Veale, Alessia Golluscio, Katheryn Grand, John M. Graham Jr, Alistair Mathie

Summary: This study describes a novel variant in the KCNB1 gene associated with global developmental delays, mild hypotonia, and joint laxity but without seizures. The variant leads to a gain-of-function of the K(V)2.1 channel with altered steady-state inactivation and reduced sensitivity to guanxitoxin-1E.

FRONTIERS IN PHARMACOLOGY (2022)

Article Biochemistry & Molecular Biology

Block of TREK and TRESK K2P channels by lamotrigine and two derivatives sipatrigine and CEN-092

Yvonne Walsh, Michael Leach, Emma L. Veale, Alistair Mathie

Summary: In this study, the inhibitory effects of the anticonvulsant lamotrigine, sipatrigine, and CEN-092 on TREK and TRESK K2P channels were investigated. Sipatrigine was found to be a more potent inhibitor compared to lamotrigine, with slight differences in potency between TREK-1 and TRESK channels. Mutation of certain residues affected the inhibition by sipatrigine and lamotrigine, indicating different mechanisms of action for these compounds.

BIOCHEMISTRY AND BIOPHYSICS REPORTS (2021)

暂无数据